ライフサイエンスコーパス: event-free survival

1 he primary outcome was investigator-assessed event-free survival.

2 denocarcinoma rarely relapsed after a 3-year event-free survival.

3 agnosis of which were highly associated with event-free survival.

4 iations with disease progression and reduced event-free survival.

5 (P=0.036) were independently associated with event-free survival.

6 f the bundled-payment program on overall and event-free survival.

7 The main outcome of interest was event-free survival.

8 s, CABG affords better major adverse cardiac event-free survival.

9 ed with increased toxicity without improving event-free survival.

10 vHD; overall survival; and chronic-GvHD-free event-free survival.

11 The primary end point was event-free survival.

12 The main outcome was event-free survival.

13 compared with patients with WBS, with median event-free survival 1.1 (0.3-5.9) versus 4.7 (2.4-13.3)

14 The primary outcome was event-free survival 2 years after HSCT.

15 .9% [75.8-93.2]; p=0.0161) and poorer 5-year event-free survival (22.2% [CI 5.6-45.9] vs 62.0% [50.4-

16 2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%

17 %, 44.8%, 19.5%, respectively; P < .001) and event-free survival (40.6%, 36.0%, 18.1%, respectively;

18 had numerically but not statistically higher event-free survival (62% versus 46%, P=0.087; hazard rat

19 s needing scar dechanneling alone had better event-free survival (80% versus 62%) and lower mortality

20 tage point (95% CI -2 to 3) change in 5-year event-free survival (89% vs 88%).

21 BI patients achieved significantly prolonged event-free survival (90.1% [95% confidence interval, 88.

22 diatric clinical trials have improved 5-year event-free survival above 85% and 5-year overall surviva

23 ed overall survival and subgroup analyses of event-free survival according to disease duration at scr

24 We aimed to assess event-free survival after high-dose chemotherapy with bu

25 s (interquartile range: 7-16 months), median event-free survival after IRE was 8 months (95% confiden

26 Event-free survival after relapse was inferior in patien

27 Five-year event-free survival after SLN alone was 93% with no isol

28 to 7-year period, significant improvement in event-free survival after surgical revascularization for

29 rtension is independently associated with CV event-free survival among individuals undergoing evaluat

30 otherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 m

31 The primary endpoint was 3-year event-free survival, analysed by intention to treat.

32 rate, duration of response, and overall and event-free survival analyses were by intention-to-treat.

33 5-year event-free survival and 5-year overall survival were est

34 th inferior transformation-free survival and event-free survival and an independent predictor of infe

35 ed risk stratification trees based on 5 year event-free survival and clinical applicability.

36 The hazard ratio for event-free survival and duration of response (P = .0020

37 The 3-year event-free survival and OS rates were 83.2% (95% CI, 79.

38 Event-free survival and overall survival (OS) hazard rat

39 Risk group predicted event-free survival and overall survival (p<0.0001).

40 standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children

41 ut pulmonary nodules, enabling us to compare event-free survival and overall survival between groups

42 dergo HSCT (45.1% [28.4-60.5], p=0.013), but event-free survival and overall survival did not differ

43 OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multiple coh

44 (n = 258) was 75.1 months; respective 5-year event-free survival and overall survival rates (95% CI)

45 The 5-year event-free survival and overall survival rates for the 5

46 The 5-year event-free survival and overall survival were 91.4% (95%

47 Event-free survival and overall survival were determined

48 follow-up of 6.5 years (IQR 4.9-7.9), 5-year event-free survival and overall survival were: 88.9% (95

49 trolled trials to estimate lifetime gains in event-free survival and overall survival with comprehens

50 hen projected incremental long-term gains in event-free survival and overall survival with comprehens

51 diagnosis <2 years) results in satisfactory event-free survival and overall survival, and to correla

52 aim was to establish the association between event-free survival and patients' minimal residual disea

53 s) for the effects of radiotherapy timing on event-free survival and subgroup interactions were combi

54 We aimed to identify predictors of event-free survival and survival with acceptable hrQoL (

55 Clinical efficacy assessments included event free survival, and change from baseline of two ass

56 All 24 (100%) patients met 12-month event-free survival, and nine had sufficient follow-up d

57 ted with the International Prognostic Index, event-free survival, and number of circulating Tregs.

58 ed to investigate time to local progression, event-free survival, and OS.

59 icacy in terms of time to local progression, event-free survival, and overall survival (OS).

60 cluding primary refractoriness and relapse), event-free survival, and overall survival.

61 y secondary endpoints were overall survival, event-free survival, and progression-free survival and s

62 y efficacy end point of the study was 3-year event-free survival, and results were analyzed on an int

63 , duration of response, progression-free and event-free survivals, and safety.

64 chemotherapy with or without rituximab, with event-free survival as the primary end point.

65 emission with incomplete recovery), inferior event-free survival as well as overall survival in both

66 We used a harmonised definition of event-free survival, as the time from randomisation unti

67 ed an overall response, a complete response, event-free survival at 12 months and 24 months from enro

68 Event-free survival at 2 years was 77.0% (95% CI 72.1-82

69 late relapses that occurred after achieving event-free survival at 24 months (EFS24).

70 Event-free survival at 3 years was 93.9% (95% confidence

71 Overall and event-free survival at 3 years were 83.9% and 80.4%, res

72 Starting from randomization, the rate of event-free survival at 4 years was 79% (95% confidence i

73 ints of this study were progression-free and event-free survival at 5 years.

74 ypass graft (CABG), with improved long-term, event-free survival attributable to use of the left inte

75 Event-free survival based on interim PET/CT (RIW) respon

76 There was no significant difference in event-free survival between recipients of transplants fr

77 Investigators supplied results for event-free survival, both overall and within predefined

78 70.0 ng/mmol) was associated with 88% 5-year event-free survival compared with 50% with high urinary

79 gnificantly worse overall survival (OS), and event-free survival compared with B-other with a 5-year

80 ents with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-l

81 vorable biology (n = 61) had superior 3-year event-free survival compared with patients with one or m

82 0.65; P=0.012) and greater discrimination of event-free survival (concordance index, 0.61 versus 0.56

83 After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, an

84 patients, Kaplan-Meier major adverse cardiac event-free survival curves demonstrated a significant be

85 One-year Kaplan-Meier estimates of adverse event-free survival (death, heart failure hospitalizatio

86 The primary end point of HALT-MS is event-free survival defined as survival without death or

87 The primary endpoint was event-free survival, defined as being alive without graf

88 Event-free survival did not differ between treatment gro

89 d points of progression-free survival (PFS), event-free survival, duration of response, and overall s

90 alysis, patients with preeclampsia had worse event-free survival during 1-year follow-up (P=0.047).

91 erapy-led trial (CNS9204) had a shorter mean event free survival (EFS) (2.7 versus 8.6 years; p = 0.0

92 nts with concurrent DLBCL and FL had similar event-free survival (EFS) (hazard ratio [HR] = 0.95) and

93 Five-year event-free survival (EFS) +/- SE (0.40 +/- 0.01) and ove

94 We developed a risk score to predict event-free survival (EFS) after allogeneic hematopoietic

95 The primary objective was 1-year event-free survival (EFS) after HLA allele-matched (at H

96 nt therapy has been associated with improved event-free survival (EFS) and overall survival (OS) in e

97 ated the hazard ratios (HRs) and 95% CIs for event-free survival (EFS) and overall survival (OS) usin

98 With a median follow-up of 30.9 months, event-free survival (EFS) and overall survival (OS) were

99 s old; median follow-up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were

100 The 4-year event-free survival (EFS) and overall survival (OS) were

101 Event-free survival (EFS) and overall survival (OS) were

102 Event-free survival (EFS) and overall survival (OS) were

103 cology Group study AREN0534 aimed to improve event-free survival (EFS) and overall survival (OS) whil

104 To quantify the relationships between event-free survival (EFS) and overall survival (OS) with

105 avorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) with

106 urrence of LVSD, trends in EF and SF, 5-year event-free survival (EFS) and overall survival (OS), and

107 oxicity and the impacts of cardiotoxicity on event-free survival (EFS) and overall survival (OS).

108 ing neoadjuvant chemotherapy (NAC), and both event-free survival (EFS) and overall survival (OS).

109 Four-year event-free survival (EFS) and overall survival estimates

110 The 5-year event-free survival (EFS) and overall survival estimates

111 en's Oncology Group trial ACNS0121 estimated event-free survival (EFS) and overall survival for child

112 We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clin

113 Meier estimates of overall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8

114 Purpose To investigate whether event-free survival (EFS) can be maintained among childr

115 months is feasible and favorably influences event-free survival (EFS) compared with historical contr

116 r all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36

117 The primary analysis was event-free survival (EFS) for patients < 36 months of ag

118 The median event-free survival (EFS) for the entire study populatio

119 assessed whether augmenting therapy improved event-free survival (EFS) for these patients.

120 The primary objective of the trial was event-free survival (EFS) from randomization.

121 ad morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0

122 ients with CNS-negative disease had a 5-year event-free survival (EFS) of 53% +/- 5% and a 5-year ove

123 ssigned to Capizzi methotrexate had a 5-year event-free survival (EFS) of 82% versus 75.4% (P = .006)

124 s with end-induction MRD <0.01% had a 5-year event-free survival (EFS) of 87% +/- 1% vs 74% +/- 4% fo

125 h embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%.

126 We sought to determine the effect on event-free survival (EFS) of staging variables, extent o

127 The 6-year event-free survival (EFS) rate for all patients enrolled

128 MRD-based standard-risk patients, the 5-year event-free survival (EFS) rate was 93% (SE 2%), the 5-ye

129 Overall survival (OS) and event-free survival (EFS) rates at 10 years were, respec

130 9% for TRIL and 41% for DL (P = .78); 4 year event-free survival (EFS) was 27% for TRIL and 27% for D

131 sus 71%, respectively (P = .007), and 5-year event-free survival (EFS) was 51% versus 58% (P = .026).

132 Five-year event-free survival (EFS) was 75.0% in patients with 1q

133 relapses at a median of 11.5 months; 5-year event-free survival (EFS) was 77% (range, 62% to 87%).

134 Median event-free survival (EFS) was 78.1 months (95% confidenc

135 r overall survival was 95.5%, and the 5-year event-free survival (EFS) was 89.8%.

136 The 3-year overall survival was 94%, and event-free survival (EFS) was 91%.

137 The early (P = .02) primary end point of event-free survival (EFS) was evaluated 6 months after c

138 Three-year overall survival and event-free survival (EFS) were 95% and 82%, respectively

139 n and ocular survival, patient survival, and event-free survival (EFS) were calculated and then compa

140 ic factors, early metabolic change, pCR, and event-free survival (EFS) were examined (log-rank test).

141 No significant differences in OS and event-free survival (EFS) were found when comparing ISM,

142 Event-free survival (EFS), an earlier prostate-specific

143 Overall survival (OS), event-free survival (EFS), and disease-free survival (DF

144 with decreased 3-year overall survival (OS), event-free survival (EFS), and relapse risk from the end

145 The primary endpoint was event-free survival (EFS), and secondary endpoints were

146 emia of Down syndrome (ML-DS) have favorable event-free survival (EFS), but experience significant tr

147 Secondary end points included 5-year event-free survival (EFS), distant disease-free survival

148 Treatment outcomes included event-free survival (EFS), overall survival (OS), and cu

149 loid leukemia (AML) is associated with worse event-free survival (EFS), overall survival (OS), and cu

150 Ph(-) had worse failure-free survival (FFS), event-free survival (EFS), transformation-free survival

151 Primary end points were event-free survival (EFS), treatment discontinuation, no

152 vant therapy, and reports of both pCR and an event-free survival (EFS)-type outcome.

153 d pretreatment risk factors with HL-specific event-free survival (EFS).

154 ls defined using RNA sequencing with pCR and event-free survival (EFS).

155 CS of more than 2 being associated with poor event-free survival (EFS).

156 The main end point was event-free survival (EFS).

157 The primary end point was event-free survival (EFS).

158 Other outcomes of interest included event-free survival (EFS).

159 ethnicity-were evaluated for their impact on event-free survival (EFS).

160 The primary outcome was event-free survival (EFS); defined as no clinical or rad

161 Event-free survival (EFS, primary endpoint) and other cl

162 ing the greatest prognostic significance for event-free survival (EFS, the main endpoint of the IELSG

163 vage therapy (37% vs 26%; P = .07) and lower event-free survival (EFS; 4-year EFS, 31% vs 43%; P < .0

164 ses to induction treatment reached excellent event-free survival (EFS; 72% v 65%) and overall surviva

165 (89% +/- 3% vs 90% +/- 4%; Plog-rank = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog

166 dverse overall survival (OS; P = 0.0441) and event-free survival (EFS; P = 0.0114) compared with low

167 Primary end points were event-free survivals (EFS).

168 correlated with immune cell infiltration and event-free-survival (EFS).

169 ge 1 tumors had an excellent outcome (5-year event-free survival [EFS] +/- standard deviation [SD], 9

170 nuation for toxicity, progression, or death (event-free survival [EFS]) were estimated.

171 pse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456)

172 with this regimen are excellent, with 2-year event-free survival estimated at 85% (95% confidence int

173 Kaplan-Meier (event-free) survival estimates were used for the endpoin

174 ach associated with an increased risk for an event-free survival event ( P = .48, P = .08, P = .065,

175 307 event-free survival events were reported (153 in the MAP

176 and were able to obtain updated results for event-free survival for 2153 patients recruited between

177 educed for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized

178 Three-year event-free survival for all patients (N = 229) was 44% a

179 SPIO enhancement was associated with reduced event-free survival for aneurysm rupture or repair (P=0.

180 The groups differed significantly in event-free survival for incident ESRD and composite outc

181 Those with multiple variants had worse event-free survival from all-cause death, cardiac transp

182 x and phenotype, we retrospectively assessed event-free survival from birth to the first clinical vis

183 d a less severe clinical course with greater event-free survival from major cardiac events (P=0.04) c

184 clophosphamide, vincristine, and prednisone, event-free survival has improved and the risk of POD24 h

185 the segregation by iPET response, where the event-free survival hazard ratio was 3.14 (95% confidenc

186 or International Prognostic Index factors in event-free survival (hazard ratio [HR] of ABC-like disea

187 for death, 0.78; one-sided P=0.009), as was event-free survival (hazard ratio for event or death, 0.

188 Median hematologic event-free survival (hemEFS) was 11.8 months and median

189 2), translating into a prolonged hematologic event-free survival (hemEFS; median, 46.1 vs 28.1 months

190 fect against RB invasion, as demonstrated by event-free survival (HR = 0.53, P = 0.007 for GC versus

191 ence interval [CI], 1.05-1.87; P < .021) and event-free survival (HR, 1.39; 95% CI, 1.05-1.82; P < .0

192 BCB1 positivity also correlated with reduced event free survival in patients with incompletely resect

193 th rituximab remained associated with longer event-free survival in a multivariate analysis.

194 The primary endpoint was 2 year event-free survival in all registered eligible patients

195 x of these genes is associated with inferior event-free survival in both patient cohorts.

196 We sought to analyze long-term chimerism and event-free survival in children undergoing transplantati

197 We aimed to investigate whether event-free survival in children with hepatoblastoma who

198 ERPRETATION: Busulfan and melphalan improved event-free survival in children with high-risk neuroblas

199 , MK-2206 evinced a numerical improvement in event-free survival in its graduating signatures.

200 that adjuvant radiotherapy does not improve event-free survival in men with localised or locally adv

201 NT5C2 mutations were associated with reduced event-free survival in multivariable analysis (hazard ra

202 of an unfavourable outcome (hazard ratio of event-free survival in patients with a MRD of >=10(-2)vs

203 isolone did not improve symptomatic skeletal event-free survival in patients with castration-resistan

204 chemotherapy (>/=10% viable tumour) improved event-free survival in patients with high-grade osteosar

205 with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblas

206 after therapy with a histologic response and event-free survival in pediatric and young adult patient

207 Event-free survival in this group was significantly lowe

208 Interpretation Our data suggest that event-free survival is improved in patients with sickle

209 MOLLI-ECV >/= the median (28.9%) had shorter event-free survival (log-rank, P=0.028).

210 Mel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall surviva

211 The primary outcome measure was event-free survival measured in the intention-to-treat p

212 cal outcomes included overall survival (OS), event-free-survival, nonrelapse mortality (NRM), and gra

213 a median follow-up of 17.1 months and median event-free survival of 17.8 months.

214 n = 92, P < .0001) and 4-year probability of event-free survival of 33 +/- 6% vs 62 +/- 5% (P = .0013

215 all survival of 73% (95% CI, 46% to 88%) and event-free survival of 49.5% (95% CI, 21% to 73%).

216 ome in the matched HFpEF cohort, with 1-year event-free survival of 62% (95% CI, 60%-64%) versus 65%

217 ated for standard-risk ALL and had a 10-year event-free survival of 88.9% (43.3-98.4).

218 This study sought to determine cardiac event-free survival of a consecutive cohort with suspect

219 The median event-free survival of all 45 evaluable treatments was 5

220 The event-free survival of male RBM20-carriers was significa

221 Event-free survival of patients diagnosed between 1990 a

222 en previously related to an increased 5-year event-free survival of pediatric pre-B acute lymphoid le

223 The primary endpoints were event-free survival, overall response, and overall survi

224 Secondary end points were event-free survival, overall survival, and safety.

225 The primary outcomes were event-free survival, overall survival, and the pattern o

226 .028), disease-free survival (P = .03), and event-free survival (P < .001).

227 gnificantly correlated with poor overall and event-free survival (P < 0.05).

228 ed with notable excess mortality and reduced event-free survival, particularly under medical manageme

229 ance therapy after transplantation prolonged event-free survival, progression-free survival, and over

230 er B-cell [GCB]-like DLBCL) were observed in event-free survival, progression-free survival, and over

231 Despite this result, the 3-year event-free survival rate (52.9% [44.6% to 62.8%] for Clo

232 The primary outcome was one-year event-free survival rate for the combined end point of d

233 f 4.6 years, there was a significantly lower event-free survival rate in patients with ASP progressio

234 e current standard of care and results in an event-free survival rate of 50% to 60%, indicating that

235 ering an overall survival rate of 95% and an event-free survival rate of 92%), and encouraging outcom

236 2-year event-free survival rate was 81% (95% CI 64-90).

237 subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high i

238 hod was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox p

239 The 5-year estimated abandonment-sensitive event-free survival rates for patients undergoing upfron

240 The 5-year event-free survival rates for patients with stages 0 to

241 t VB stroke (P = .04), with 12- and 24-month event-free survival rates of 78% and 70%, respectively,

242 5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 +/- 0.9% for dexametha

243 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) an

244 P5 expression displayed inferior overall and event-free survival rates.

245 Factors associated with event-free survival, relapse-free survival, and incidenc

246 Four-year event-free survival, relapse-free survival, and overall

247 e partitioning with univariate Cox models of event-free survival ("survival tree regression") was per

248 Symptomatic relatives had a shorter event-free survival than asymptomatic DCM relatives (P<0

249 powerful predictor of major adverse cardiac event-free survival than choice of therapy (hazard ratio

250 BG led to lower rates of 5-year survival and event-free survival than on-pump CABG.

251 th blinatumomab resulted in a higher rate of event-free survival than that with chemotherapy (6-month

252 The primary end point was 2-year event-free survival; the planned accrual was 38 patients

253 We evaluated the risk of relapse at event-free survival time points in cHL and compared the

254 ersmith Infant Neurological Examination) and event-free survival (time to death or the use of permane

255 Overall survival (OS), event-free survival, transplant-related mortality (TRM),

256 Event free survival was worse for CD56-negative compared

257 as 16.9 months (95% CI 1.5-32.3), and median event-free survival was 11.0 months (1.5-16.7).

258 40% (6/15 of evaluable patients) and median event-free survival was 17 months.

259 n follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for

260 erall survival was 4.3 years, and the median event-free survival was 2.7 years.

261 r disease-free survival was 31.2% and 16.2%, event-free survival was 21.5% and 12.9%, and overall sur

262 Median symptomatic skeletal event-free survival was 22.3 months (95% CI 20.4-24.8) i

263 de, and melphalan group had an event; 3-year event-free survival was 50% (95% CI 45-56) versus 38% (3

264 Event-free survival was 50.6% versus 56.6% at 3 years an

265 edian follow-up of 44 months (26-53), 4-year event-free survival was 59% (95% CI 48-73); 69% (54-87)

266 In all 122 patients, 5-year event-free survival was 59.1% (95% CI 50.5-69.1), 5-year

267 er a median follow-up of 5 years, the 3-year event-free survival was 62% versus 65% ( P = .83).

268 In patients with T-LL, 3-year event-free survival was 63.3% (95% CI, 54.2% to 71.0%),

269 2-year event-free survival was 64.0% (95% CI 56.0-70.9) in the

270 e incidence of EBRT was 5.9% (SE +/- 3), and event-free survival was 69.2% (SE +/- 27.2).

271 Estimated 2-year event-free survival was 69.7% (95% CI 66.2-73.0).

272 37 months (IQR 30-44), the estimated 2 year event-free survival was 75% (95% CI 63-84).

273 months), the overall survival was 91.4%, and event-free survival was 81.4%.

274 e survival was 92% (95% CI 79-97) and 5-year event-free survival was 88% (72-95).

275 Estimated 4-year event-free survival was 89.7% (95% confidence interval 8

276 4-year event-free survival was 92% (95% CI 79-97) and 5-year ev

277 Event-free survival was also worse in patients condition

278 Event-free survival was defined as avoidance of external

279 Two-year event-free survival was estimated at 49.0% (95% confiden

280 1%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group t

281 s, the meta-analysis showed no evidence that event-free survival was improved with adjuvant radiother

282 After a median follow-up of 30 months, event-free survival was longer in the rituximab group th

283 Event-free survival was lower with increasing age at tra

284 -up of 17.25 months (IQR 0.50-30.40), median event-free survival was not reached (95% CI 7.93-NR).

285 After a median follow-up of 4 years, event-free survival was reduced in genetic versus patien

286 the provisional risk classification, 10-year event-free survival was significantly worse for patients

287 By Kaplan-Meier analysis, event-free survival was significantly worse in patients

288 Cumulative event-free survival was significantly worse in patients

289 Event-free survival was similar among TERT-high, ALT(+),

290 Event-free survival was worse in recipients aged 13 year

291 Major cardiovascular adverse events-free survival was worse in patients with MVO (P=0

292 One-year overall and event-free survival were 63% and 46%, respectively.

293 nfiltrating lymphocytes (TILs) and five-year-event-free-survival were examined.

294 he primary endpoint was symptomatic skeletal event-free survival, which was assessed in the intention

295 The primary end point was event-free survival (with an event defined as disease pr

296 The 5-year event-free survival (with standard error) did not differ

297 nduction was associated with increased early event-free survival, with no difference in long-term pat

298 ters differ significantly in terms of 4-year event-free survival, with the lowest methylation cluster

299 v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.

300 % v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7%